Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Allergy (PEPITES)

Official Title: A Double-blind, Placebo-controlled, Randomized Phase 3 Pivotal Trial to Assess the Efficacy and Safety of Peanut Epicutaneous Immunotherapy With Viaskin Peanut in Peanut-allergic Children

This study is being done to see if Epicutaneous Immunotherapy with the Viaskin Peanut patch is safe and to find out how well it reduces or prevents immediate allergic reactions after exposure to peanuts. Viaskin Peanut is a skin patch that contains dry peanut proteins. This study is for children ages 4 through 11 years old with peanut allergy.

Pongracic, Jacqueline A., MD

Contact Information:

Jacqueline Pongracic, MD

Principal Investigator